239 results about "Prostatic Cancers" patented technology

The invention belongs to the field of characterization learning, and particularly relates to a prostate cancer diagnosis method based on a multimodal large model prompt learning mechanism. Comprising the following steps: step 1, data preprocessing; 2, key frames and similarity are calculated, and irrelevant editing is compressed; step 3, text and image alignment training; step 4, a test stage; according to the method, a similarity-based screening mechanism is provided, ultrasonic videos under coarse-grained labels are preliminarily screened under segmentation of a large model, and focus areas are focused on in time sequence; meanwhile, a pre-processing mechanism based on a large model is provided, and the influence of a large amount of irrelevant information existing in prostate ultrasonic image scanning on the model is compressed at a data end, so that the diagnosis effect of the model is improved.

A real-time artificial intelligence (AI) framework is provided for the automated analysis of radiological images and detection of disease, such as extracapsular extension (ECE) in prostate cancer. The system includes a dual deep learning architecture comprising a first convolutional neural network (CNN) for identifying diagnostically relevant image slices from three-dimensional MRI data, and a second CNN for classifying disease presence based on those slices. A preprocessing pipeline standardizes and harmonizes image input, and cropping algorithms isolate the region of interest for enhanced model performance. This framework enables scalable, high-accuracy diagnosis across various imaging modalities including but not limited to MRI, CT, PET, ultrasound, and diverse disease types, improving clinical decision-making and supporting integration into real-time radiology workflows.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

The invention relates to the technical field of artificial intelligence, and discloses a prostate cancer early screening model construction method based on deep learning. The method comprises the following steps: acquiring a multi-modal magnetic resonance imaging data set; segmenting the positive focus and encoding the positive focus into pathological state vectors; constructing a conditional generative adversarial network under pathological state constraints to generate a synthetic focus image with specified pathological features; seamlessly embedding the synthetic focus into a healthy background through a gradient domain fusion algorithm to generate a high-reality positive sample; and integrating the original and synthetic samples to train a three-dimensional convolutional neural network screening model. The system comprises a multi-modal image acquisition module, a pathological feature vectorization module, a condition generation module, a focus fusion module and a model training deployment module. According to the method, the model generalization ability and the early screening accuracy are remarkably improved, and the missed diagnosis rate is effectively reduced.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention discloses application of a small molecular compound secalonic acid B in inhibiting Skp2 protein and resisting prostate cancer cell metastasis, and belongs to the technical field of medicines. The research finds that secalonic acid B can obviously reduce the half-life period of Skp2, accelerate the degradation speed of Skp2 and reduce the protein level of Skp2 in DU145 cells by enhancing the polyubiquitination process on Skp2 protein. The secalonic acid B induces proteasome degradation of Skp2 through a multi-ubiquitination pathway of a K48 chain, so that tumor cell metastasis is inhibited, and the effect of resisting prostatic cancer is achieved. The invention discloses an action mechanism of secalonic acid B in inhibiting Skp2 protein and resisting prostate cancer cell metastasis, lays a theoretical foundation for research and development of drugs for inhibiting Skp2 protein and treating prostate cancer, and provides a new strategy for treatment of prostate cancer.

The present invention relates to crystalline particles of N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazol-3-carboxamide (I) having a specific surface area (SSA) in the range of from about 8 to about 16 m2 / g, preferably from about 10 to about 15 m2 / g, and to a process for preparing said particles. Compound (I) is potent androgen receptor (AR) modulators, which are useful as medicaments, for example in the treatment of prostate cancer.

The present application relates to the technical field of medical imaging processing, in particular to a puncture planning method and system based on prostate multi-modal imaging and a storage medium, comprising: planning a first path with a prostate cancer region as a target point in prostate multi-modal imaging; acquiring an ultrasound image of a puncture needle in a running process according to the first path in real time; detecting and segmenting the puncture needle in the ultrasound image and determining positioning information of a needle tip of the puncture needle; registering the first path to the ultrasound image in the prostate multi-modal imaging and determining correction information of the puncture needle running process by using the first path and the positioning information of the needle tip of the puncture needle. The present application plans a puncture path of prostate cancer on prostate multi-modal imaging, realizes providing guiding information for puncture, and accurately positions a puncture needle shape and positioning information in a puncture guiding process through ultrasound guiding, so as to accurately guide or correct information in a puncture process by using a planned path.

The invention discloses 5 alpha-reductase degradation molecules as well as a preparation method and application thereof, four 5 alpha-reductase degradation molecules can realize thorough removal of zymoprotein by inducing proteasome-dependent degradation of 5 alpha-reductase instead of only inhibiting the activity of the 5 alpha-reductase, so that a more lasting treatment effect is obtained; under the condition of equal dosage, the effect of the 5 alpha-reductase degradation molecule on treating the benign prostatic hyperplasia is superior to that of the traditional inhibitor finasteride; the four kinds of 5 alpha-reductase degrading molecules can effectively degrade 5 alpha-reductase protein and remarkably inhibit development of benign prostatic hyperplasia, have good biological safety and provide new strategies and candidate drugs for treatment of diseases related to 5 alpha-reductase such as benign prostatic hyperplasia, prostatic cancer, androgenetic alopecia and acne.

The present invention belongs to the field of biomedicine technology, and relates to the application of the Lnc-FLJ gene in the treatment of castration-resistant prostate cancer. The application of the Lnc-FLJ gene inhibitor in the preparation of prostate cancer drugs. The present invention discovered for the first time that Lnc-FLJ can inhibit the proliferation and autophagy of castration-resistant prostate cancer. Lnc-FLJ is more highly expressed in castration-resistant prostate cancer cells and prostate cancer tissues with higher malignancy. Inhibiting Lnc-FLJ can inhibit the occurrence and development of castration-resistant prostate cancer. The preparation of Lnc-FLJ small molecule inhibitor shRNA is used to treat castration-resistant prostate cancer and cancer insensitive to enzalutamide, thereby inhibiting the AR signaling pathway. The present invention provides new ideas for further studying the pathogenesis of castration-resistant prostate cancer and the function of the Lnc-FLJ gene, and provides a new direction for the development of castration-resistant prostate cancer drugs.

The invention discloses a double-target chimeric antigen receptor capable of simultaneously targeting TLL1 and B7H3, a CAR-T cell and application of the double-target chimeric antigen receptor. The chimeric antigen receptor is a fusion protein which is sequentially composed of Omburt-scFv (SEQ ID NO: 1) targeting B7H3, a CD8 alpha hinge region and transmembrane region, a 4-1BB costimulatory domain, a CD3 zeta signal domain and TLL1-scFv (SEQ ID NO: 6) targeting TLL1 from an N terminal to a C terminal. The TLL1-scFv can be efficiently combined with TLL1 protein, can inhibit a TGF-beta signal channel and block prostate cancer cell migration, and is integrated into CAR of targeted B7H3, so that the double-target CAR-T cell with direct killing and immune microenvironment regulation functions is successfully constructed. The CAR-T cell has a remarkable killing effect on a prostate cancer cell line DU145, can be strongly activated after being co-cultured with a target cell and secretes a large amount of IFN-gamma and TNF-alpha, and shows high immunocompetence. The invention provides a new synergistic immunotherapy strategy for the B7H3-positive prostate cancer with the TGF-beta signal channel activated.

The invention specifically discloses application of VGF as a diagnostic biomarker for prostatic cancer, and relates to the technical field of biological medicines. The secretory protein VGF is identified to be remarkably up-regulated in prostatic fluid of a prostatic cancer patient before puncture for the first time, high expression of the secretory protein VGF is proved to be independently related to shorter progression-free lifetime and total lifetime through a public database, and a brand-new liquid biopsy marker is provided for PCa non-invasive early screening and prognosis evaluation.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazo-pyridine structure, or compounds having a pyridinyl-purine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and are useful as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes (e.g., any type or form of diabetes, including type-1 or type-2), autoimmune diseases, inflammatory disorders (e.g., airway inflammation), cancer (e.g., glioblastoma, prostate cancer), diabetes, and other diseases.

Disclosed herein are methods including LATS kinase inhibitors or TIP60 inhibitors to perturb lineages within heterogenous tumors (e.g., prostate cancer) and enhance responsiveness to Androgen Receptor Signaling Inhibitor (ARSI) therapy or other therapeutic agents that target adenocarcinoma lineages (e.g., PSMA or STEAP1-expressing tumor cells.

The present disclosure provides methods for treating prostate cancer patients with an anti-STEAP1 antigen-binding protein such as xaluritamig either as monotherapy or in combination with another therapeutic agent.

Methods of treating prostate cancer, including castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, comprising administering an effective amount of an androgen receptor (AR) antagonist and an effective amount of a nonsteroidal selective glucocorticoid receptor modulator (SGRM) are disclosed. The AR antagonist may be enzalutamide. The SGRM may be an octahydro fused azadecalin compound, such as exicorilant, ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone which has the structure: The AR antagonist and the SGRM may be administered once per day, and may be administered with food. Enzalutamide doses may be 150-200 mg / day, e.g., 160 mg / day. Exicorilant doses may be 100-350 mg / day, e.g., 240 mg / day, or 280 mg / day, or 320 mg / day.

The present invention relates to a solid dispersion comprising enzalutamide or its pharmaceutically acceptable salts, hydroxypropyl methylcellulose phthalate (HPMCP), soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol), surfactant, and optionally at least one pharmaceutically acceptable excipient. The present invention also relates to a pharmaceutical composition comprising the solid dispersion of enzalutamide and its use for treating prostate cancer. The present invention further relates to a process for preparation of the solid dispersion of enzalutamide and the pharmaceutical composition comprising the solid dispersion of enzalutamide.

Systems and methods for evaluating progression of an anatomical object over a plurality of timepoints are provided. Longitudinal medical images of an anatomical object of a patient acquired over a plurality of timepoints are received. For each respective timepoint of the plurality of timepoints, features are extracted from the longitudinal medical images acquired at the respective timepoint using a machine learning based feature extractor network and the anatomical object in the longitudinal medical images acquired at the respective timepoint is analyzed based on the extracted features using a machine learning based prediction model. Progression of the anatomical object over the plurality of timepoints is evaluated based on results of the analyses using a machine learning based progression model. The evaluation of the progression of the anatomical object over the plurality of timepoints is output.

The application discloses a prostate cancer bone metastasis risk prediction diagnosis device and relates to the technical field of prostate cancer diagnosis. The application comprises a diagnosis table, two support rods are symmetrically arranged on one side of the diagnosis table, support plates are arranged on the sides of the two support rods away from each other, an adjusting assembly for adjusting the positions of the support plates is arranged on the support rods, a connecting block is fixed at one end of the diagnosis table, a movable groove is arranged in the connecting block, movable blocks are fixed at the bottom ends of the support rods, and the movable blocks are slidably connected in the movable groove. When rectal digital examination is needed for a patient, the patient is laid on the diagnosis table, the bent parts of the legs of the patient are respectively arranged on the two support plates, the two movable blocks are driven to move away from each other through a driving mechanism, the legs of the patient are bent and separated, and the patient is in a supine position, so that rectal digital examination in a supine position is facilitated.

The application discloses a prostate cancer patient pelvic floor muscle recovery evaluation system based on artificial intelligence, which comprises an original data collection module, an original data optimization module, a time sequence double-end recovery evaluation model establishment module, a recovery evaluation model performance optimization module and a whole-cycle intelligent recovery evaluation module. The application relates to the technical field of medical data processing, in particular to a prostate cancer patient pelvic floor muscle recovery evaluation system based on artificial intelligence. The scheme innovatively proposes a time sequence double-end recovery evaluation model combining an in-hospital baseline end and a home continuous time sequence end, improves the real-time performance of patient pelvic floor muscle recovery evaluation, extracts short-term time sequence recovery features by using a bidirectional long short-term memory network, extracts long-term time sequence recovery features by combining an improved convolution residual network with a parallel activation function, significantly improves the accuracy of the recovery evaluation results, and introduces an improved optimization algorithm combined with a dynamic local search strategy, thereby significantly improving the stability and accuracy of the output results of the model.

The present invention relates to compounds of formula (I) wherein A is a 3-10 membered carbocyclic ring or a 4-12 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N or S; B is any one of the following groups (1), (2) or (3); C is any one of the following groups (1'), (2'), (3') or (4'); G1 is CH2, NH or O; G2 and G3 are independently of each other CH or N; Z is -C(O)-, -SO2-, -C 1‑3 alkyl- or -CH2-C(O)-; L is a bond, -C 1‑7 alkyl- or -C 1‑7 alkenyl-. The compounds of formula (I) are inhibitors of cytochrome P450 monooxygenase 11A1 (CYP11A1). The compounds are useful as medicaments for the treatment of steroid receptor, e.g. androgen receptor or estrogen receptor dependent diseases and disorders such as cancer including prostate cancer and estrogen cancer.

The present invention belongs to the field of biochemistry and discloses a polypeptide comprising: (I) an amino acid sequence as shown in SEQ ID No. 1; or (II) an amino acid sequence formed by adding one or more amino acids before or after the amino acid sequence as shown in (I); or (III) a cell-penetrating polypeptide obtained by combining the polypeptide shown in (I) or (II) with a cell-penetrating peptide. The polypeptide significantly inhibits the growth and proliferation of two prostate cancer cell lines (DU145 and PC3), as well as RNA alternative splicing. The present invention also discloses a drug containing the polypeptide and its uses.

The application relates to the technical field of biological medicine, and discloses a targeted ferroptosis-inducing conjugate as well as a preparation method and application thereof. The structural formula of the conjugate is as follows: the conjugate contains a prostate cancer targeting peptide segment WHDGFK, and is connected with an iron death-inducing antibacterial peptide KRIVKWIIKLLR through a disulfide bond, so that the conjugate has tumor targeting and microenvironment response release functions, not only endows the antibacterial peptide KRIVKWIIKLLR with tumor selective delivery capacity, but also realizes specific release of the active peptide in target cells by reducing the disulfide bond by using high-concentration glutathione (GSH) in tumor cells, thereby synergistically enhancing the antitumor effect and reducing the systemic toxicity.

The invention belongs to the technical field of organic synthesis and medicinal chemistry, and particularly relates to a synthesis method of a novel polycyclic aromatic hydrocarbon derivate 2, 6-di-tert-butyl pyrene and indolizine phenothiazine compound and application of the compound in the aspect of anti-cancer drugs. The synthesis process is simple and convenient, conditions are mild, and the yield is ideal. Pharmacodynamic evaluation shows that the compound shows strong inhibitory activity on various human cancer cell lines, and the IC50 values are respectively cervical cancer Hela cells (0.17 mu M), lung cancer A549 cells (0.3 mu M), prostatic cancer PC-3 cells (0.42 mu M) and liver cancer HepG2 cells (10.79 mu M), which are respectively reduced by 109 times, 173 times, 35 times and 1.8 times compared with positive control drug cis-platinum. In addition to efficiently inhibiting cancer cells, the compound has low toxicity to normal cells, meets the basic requirements of excellent anti-cancer drugs, and shows important application value and potential in the field of research and development of novel anti-cancer drugs.

Methods of treating non-metastatic castration-resistant prostate cancer in a subject having severe liver damage are provided.SOLUTION: Provided are methods of treating non-metastatic castration-resistant prostate cancer in a subject with severe hepatic impairment with an androgen receptor inhibitor comprising 4 - [7 - (6-cyano-5-trifluoromethylpyridin-3-yl) - 8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl] - 2-fluoro-N-methylbenzamide (apalutamide).SELECTED DRAWING: None

The application discloses a kit for predicting the curative effect of immunotherapy on prostate cancer patients, which comprises reagent A, reagent B, reagent C, reagent D, reagent E and reagent F; the reagent A is a PBS buffer solution; the reagent B is a lymphocyte separation medium; the reagent C is a red blood cell lysis solution; the reagent D is a cell surface CD3 flow antibody; the reagent E is a cell surface CD19 flow antibody; and the reagent F is a 1% polyformaldehyde solution in terms of mass percentage concentration. The application further discloses an application method of the kit, which comprises the following steps: collecting venous blood of prostate cancer patients; extracting peripheral blood mononuclear cells (PBMC) in the venous blood of the prostate cancer patients; incubating the flow antibody; and performing flow cytometry analysis. The kit and the application thereof are simple and fast, non-invasive, repeatable, low in cost and short in detection time.

This is a method for treating prostate cancer. Specifically, it involves the use of the compound shown in Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a drug for treating metastatic castration-resistant prostate cancer. [Formula 1] JPEG2026521901000005.jpg32155

The application discloses a fine segmentation method for prostate and internal lesion areas based on large pathological sections, and specific steps are as follows: step 1, sequentially performing fixation, paraffin embedding, continuous transverse sectioning and HE staining operations on the whole tissue; step 2, extracting an HE staining image; step 3, sequentially scanning the pathological sections in step 2 into digital pathology; step 4, processing the digital pathology; step 5, performing image registration and three-dimensional image reconstruction on analysis results of multiple pathological sections processed in step 4; step 6, training a magnetic resonance multi-modal sequence segmentation model; step 7, extracting features of normal prostate tissue and lesion tissue in three sequences; step 8, acquiring high-risk factor information and quantifying features; step 9, constructing a sample feature matrix; and step 10, predicting the malignancy degree of prostate cancer. The method can realize more accurate benign and malignant evaluation of prostate lesions and prediction of the malignancy degree of prostate cancer.

The invention discloses a marker group for screening and diagnosing prostatic cancer and application of the marker group, and belongs to the technical field of molecular biology. The marker group comprises at least four of polypeptides as shown in sequences SEQ ID NO. 1 to 46. The marker combination constructed by the invention has more excellent sensitivity and specificity when being used for auxiliary diagnosis and early screening of prostatic cancer. The auxiliary diagnosis result of the method is superior to that of a PCa diagnosis mode using mp-MRI (sensitivity is 83.45%, and specificity is 92.94%) recommended by a PCa diagnosis and treatment guide and a prostate image report data system of the European urinary society at present. An early screening result is superior to that of serum PSA (Prostate Sequence Assay) examination which is currently used as a first choice means for prostate cancer screening, the critical value is 4.0 ng / mL (strong recommendation in Guidelines and medium evidence grading), the sensitivity is 72.84%, and the specificity is 81.10%.